Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 20Carcinoma, Hepatocellular 18Breast Neoplasms 16Small Cell Lung Carcinoma 14Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Liver Neoplasms 7Neoplasm Metastasis 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Endometrial Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Carcinoma 5Biliary Tract Neoplasms 5Stomach Neoplasms 4Melanoma 4Colorectal Neoplasms 4Cholangiocarcinoma 4Prostatic Neoplasms 3Neoplasms by Site 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Cervical Neoplasms 2Turcot syndrome 2Thyroid Neoplasms 2Thoracic Neoplasms 2

Interventions

pembrolizumab 3romidepsin 2Specimen Handling 2Melphalan 2Gemcitabine 2Etoposide 2Cyclophosphamide 2Biopsy 210-propargyl-10-deazaaminopterin 2tazemetostat 1talimogene laherparepvec 1prednylidene 1fludarabine 1etoposide phosphate 1durvalumab 1deltacortene 1cc-486 1carmustine, poliferprosan 20 drug combination 1belinostat 1Whole-Body Irradiation 1Triamcinolone 1Tacrolimus 1Prednisone 1Pharmacokinetics 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Nivolumab 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell × durvalumab × Clear all
NCT03011814 2025-09-18

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Active not recruiting
38 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡